Study Comparing Intermittent Pneumatic Compression With Manual Lymphatic Drainage in Complete Decongestive Therapy for Breast Cancer-Related Lymphedema

What this Trial Is About

Breast cancer is the most common cancer among women worldwide, and one of its major complications is breast cancer-related lymphedema BCRL. This condition can develop shortly after treatment or even years later, causing swelling, heaviness, discomfort, and reduced quality of life. Researchers are investigating how intermittent pneumatic compression IPC therapy compares to manual lymph drainage MLD, both standard parts of complete decongestive therapy CDT, to better understand IPCs role in treating BCRL. The study compares three groups one receiving the full CDT including MLD plus IPC, another receiving CDT without MLD but with IPC replacing it, and a third group receiving standard CDT with MLD alone. Treatments involve sessions five times a week for three weeks, using IPC at 20-50 mmHg pressure for 40 minutes per session when included. Total session durations vary from 75 to 115 minutes depending on the group and whether IPC is used alongside or instead of MLD. Participants will be monitored before and after the treatment period with measurements of arm volume and circumference, shoulder range of motion, and quality of life assessments. Other evaluations include questionnaires on arm function, swelling, heaviness, tightness, pain, and patient satisfaction. The study aims to assess acute effects within three weeks of starting rehabilitation, with all safety and outcome data collected under medical supervision.

Comparison of IPC Therapy as an Alternative or an Adjunct to MLD Within CDT for BCRL